The discovery could lead to novel treatments that efficiently eliminate blood cancer cells in acute myeloid leukemia (AML), without harming healthy blood cells.
Researchers have discovered how a protein in the body plays a key role in AML -- an aggressive cancer of white blood cells with very poor survival rates.
Study - Protein - YTHDF2 - Disease - Cells
The study showed that the protein, known as YTHDF2, is needed to trigger and sustain the disease, but is not needed for healthy cells to function. This identifies YTHDF2 as a promising drug target for leukemia.
A team of researchers jointly led by the University of Edinburgh and Queen Mary University of London carried out a series of experiments to understand the role of YTHDF2 in blood cancer.
Tests - Blood - Samples - Leukemia - Patients
Tests in blood samples donated by leukemia patients showed that the protein is abundant in cancer cells, while experiments in mice found that the protein is required to initiate and maintain the disease.
Further tests enabled scientists to determine the biological pathway by which interfering with the function of YTHDF2 selectively kills...
Wake Up To Breaking News!